Evidence insufficient on relationship of modifiable factors with risk of Alzheimer's disease

May 9, 2011, JAMA and Archives Journals

The available evidence is insufficient to draw firm conclusions about the association of modifiable factors and risk of Alzheimer's disease (AD), according to a report posted online today that will appear in the September issue of Archives of Neurology.

Estimates suggest that up to 5.3 million people in this country may have AD, and this number will likely increase as grow older. In fact, "age is currently the strongest known risk factor for AD," write the authors. Variation in the (APOE) gene is also associated with the risk of developing AD. However, existing research to ascertain other for the condition has been less conclusive.

From April 26 to 28, 2010, the National Institutes of Health convened a State-of-the-Science Conference to examine studies of potential AD risk factors and possible preventive measures. The conference evaluated existing English-language research found in MEDLINE and the Cochrane Database of Systematic Reviews from 1984 through October 27, 2009, as well as a formal evidence report. Topics considered were nutritional supplements and dietary factors, physical activity, other chronic conditions (diabetes, high cholesterol, ), substance use (cigarettes, alcohol), and cognitive engagement. Panelists weighed the level of evidence for each risk factor (low, moderate or high) and rated studies accordingly (low for observational studies vs. high for ).

Martha L. Daviglus, M.D., Ph.D., from Northwestern University Feinberg School of Medicine, Chicago, and colleagues summarized the panel's findings. The group determined "that currently there is no evidence of even moderate scientific quality supporting the association of any modifiable factor with reduced risk of or AD." While some studies appeared to show an increase or reduction of AD risk or progression, they were not strong enough to draw firm conclusions. The authors call for large-scale, long-term, population-based studies and clinical trials to answer these questions. "It is hoped that the panel's report will instigate rigorous high-quality research that can provide conclusive evidence on this issue," they write. "Until more conclusive results are available, individuals should continue to aim for a physically and mentally active and healthy lifestyle and prevention of the well-known major risk factors for chronic diseases."

Explore further: Evidence lacking for efficacy of memantine in treating mild Alzheimer's disease

More information: Arch Neurol. 2011;doi:10.1001/archneurol.2011/100

Related Stories

Evidence lacking for efficacy of memantine in treating mild Alzheimer's disease

April 11, 2011
An analysis of studies involving the drug memantine finds a lack of evidence for benefit when the drug is used to treat patients with mild Alzheimer disease, according to a report posted online today that will appear in the ...

Recommended for you

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

Molecular mechanism behind HIV-associated dementia revealed

January 5, 2018
For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV, according to a Northwestern Medicine study published in Nature Communications.

Mice with frequent flier miles advance the Alzheimer's cause

January 4, 2018
Alzheimer's disease wreaks emotional havoc on patients, who are robbed of their memories, their dignity, and their lives. It's financially devastating as well: care for Alzheimer's patients is predicted to top $1 trillion ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.